1365 Grady Health System, Atlanta, GA, USA.
23033 Department of Gynecology and Obstetrics, Emory University, Atlanta, GA, USA.
Public Health Rep. 2020 May/Jun;135(3):313-321. doi: 10.1177/0033354920914340. Epub 2020 Mar 30.
Despite the safety and efficacy of the human papillomavirus (HPV) vaccine, many persons are still not receiving it. The purpose of this pilot project was to evaluate the number of first doses of the 9-valent HPV (9vHPV) vaccination administered after a pharmacist-led intervention in the Adult Family Planning Clinic at Grady Health System (GHS), a large academic urban medical center in Atlanta, Georgia.
The pilot project had 3 phases: pre-intervention (November 15, 2016, through March 31, 2017), active intervention (November 15, 2017, through December 29, 2017), and post-intervention (December 30, 2017, through March 31, 2018). The pre-intervention phase was used as a historical control. The active intervention phase consisted of pharmacist interventions in the clinic and patient and health care provider education. The post-intervention phase evaluated the durability of pharmacist-led interventions performed and education provided during the active phase.
Eighty-nine first-dose 9vHPV vaccines (of the 3-dose series) were administered to young adults aged 18-26 during the project period (November 15, 2017, through March 31, 2018); none were administered during the pre-intervention phase. Of 89 patients who received a first 9vHPV vaccine dose, 20 patients also received a second 9vHPV vaccine dose. During the project period, 166 doses of 9vHPV vaccine (first, second, or third doses) were administered.
This pharmacist-led intervention led to an increase in the number of young adult patients receiving their first dose of the 9vHPV vaccination series. With the support of other health care providers, pharmacist-led initiatives can expand vaccine-related health literacy and facilitate access to immunization services.
尽管人乳头瘤病毒(HPV)疫苗安全且有效,但仍有许多人未接种该疫苗。本试点项目的目的是评估在佐治亚州亚特兰大市大型学术性城市医疗中心格莱迪卫生系统(GHS)成人计划生育诊所,由药剂师主导的干预措施实施后,9 价 HPV(9vHPV)疫苗接种的首针剂量数量。
该试点项目分为 3 个阶段:干预前(2016 年 11 月 15 日至 2017 年 3 月 31 日)、主动干预(2017 年 11 月 15 日至 2017 年 12 月 29 日)和干预后(2017 年 12 月 30 日至 2018 年 3 月 31 日)。干预前阶段作为历史对照。主动干预阶段包括在诊所开展的药剂师干预措施以及对患者和卫生保健提供者的教育。干预后阶段评估了在主动阶段实施的药剂师主导干预措施和提供的教育的持久性。
在项目期间(2017 年 11 月 15 日至 2018 年 3 月 31 日),共有 89 名 18-26 岁的年轻人接种了 9vHPV 疫苗(3 剂系列)首针;在干预前阶段没有接种。在接受首针 9vHPV 疫苗的 89 名患者中,有 20 名患者还接种了第二针 9vHPV 疫苗。在项目期间,共接种了 166 剂 9vHPV 疫苗(首针、第二针或第三针)。
这项由药剂师主导的干预措施增加了接受 9vHPV 疫苗系列首针接种的年轻患者数量。在其他卫生保健提供者的支持下,药剂师主导的举措可以提高与疫苗相关的健康素养,促进获得免疫服务。